Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 15 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2023 Filed Jan 19, 2023 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 25,446 | $40.03 | $1,018,728.07 |
DisclosureSEC source: 0001104659-23-005057 · tm233672-5_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,173 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.11, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 41,920 | $9.56 | $400,755.20 |
DisclosureSEC source: 0001104659-23-005057 · tm233672-5_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 816,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,826 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-23-005058 · tm233672-4_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 4,826 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on March 3, 2016. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 4,826 | $39.92 | $192,637.99 |
DisclosureSEC source: 0001104659-23-005058 · tm233672-4_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.90 to $40.00. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 4,826 | $9.13 | $44,061.38 |
DisclosureSEC source: 0001104659-23-005058 · tm233672-4_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,470 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 22:00 UTC |
Rubin JonathanSr. VP, Chief Medical Officer
|
GrantPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004285 · tm233672-1_4seq1.xml · derivative · entry 1 Rubin Jonathan · CIK 0001836067 · Sr. VP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2031-04-30 F1 · derivative.exercise_date: On April 30 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 22:03 UTC |
Mottola FrankSVP, Quality, GMP, Ops, IT
|
GrantPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004292 · tm233672-3_4seq1.xml · derivative · entry 2 Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2031-04-30 F1 · derivative.exercise_date: On April 30 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| January 12, 2023 Filed Jan 17, 2023 22:02 UTC |
Martin Tami TillotsonSr. V.P., Regulatory Affairs
|
GrantPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-004289 · tm233672-2_4seq1.xml · derivative · entry 2 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2031-04-30 F1 · derivative.exercise_date: On April 30 2021, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 17:00 UTC |
Hudson Frederick M.Director
|
Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 8,722 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-23-003461 · tm233200-3_4seq1.xml · derivative · entry 2 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,722 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 17:00 UTC |
Hudson Frederick M.Director
|
Exercise / conversionCommon Stock | 8,722 | $7.90 | $68,903.80 |
DisclosureSEC source: 0001104659-23-003461 · tm233200-3_4seq1.xml · nonDerivative · entry 1 Hudson Frederick M. · CIK 0001438462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 174 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-23-002317 · tm2233689-2_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,826 Underlying: Common Stock · 174 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F2 · derivative.exercise_date: The option vested in four equal annual installments beginning on March 3, 2016. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 174 | $39.90 | $6,942.60 |
DisclosureSEC source: 0001104659-23-002317 · tm2233689-2_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 174 | $9.13 | $1,588.62 |
DisclosureSEC source: 0001104659-23-002317 · tm2233689-2_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 17:01 UTC |
NEWHALL CHARLES W IIIDirector
|
Exercise / conversionDirector Stock Option (Right to Buy) · Derivative | 8,722 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-22-131398 · tm2233689-1_4seq1.xml · derivative · entry 2 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,722 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 17:01 UTC |
NEWHALL CHARLES W IIIDirector
|
Exercise / conversionCommon Stock | 8,722 | $7.90 | $68,903.80 |
DisclosureSEC source: 0001104659-22-131398 · tm2233689-1_4seq1.xml · nonDerivative · entry 1 NEWHALL CHARLES W III · CIK 0001005544 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 11,354 | $38.14 | $433,069.95 |
DisclosureSEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · nonDerivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 814,699 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.38, inclusive. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 18,472 | $9.56 | $176,592.32 |
DisclosureSEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 826,053 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document |
| December 21, 2022 Filed Dec 22, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
GrantCommon Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 807,581 F3 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 21, 2020. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 18,472 | $0.00 Strike: $9.56 | $0.00 |
DisclosureSEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · derivative · entry 8 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 18,472 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F6 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,528 | $0.00 Strike: $9.56 | $0.00 |
DisclosureSEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · derivative · entry 7 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,472 Underlying: Common Stock · 6,528 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F6 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 4,006 | $38.02 | $152,316.93 |
DisclosureSEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 791,956 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.00 to $38.09, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 20, 2022 Filed Dec 22, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 6,528 | $9.56 | $62,407.68 |
DisclosureSEC source: 0001104659-22-129580 · tm2233271-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,962 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-22-124160 · tm2231819-1_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on March 3, 2016. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 5,000 | $37.48 | $187,416.00 |
DisclosureSEC source: 0001104659-22-124160 · tm2231819-1_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.45 to $37.65, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 5,000 | $9.13 | $45,650.00 |
DisclosureSEC source: 0001104659-22-124160 · tm2231819-1_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,644 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| November 25, 2022 Filed Nov 28, 2022 22:02 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 17,794 | $0.00 Strike: $9.56 | $0.00 |
DisclosureSEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · derivative · entry 8 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 17,794 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F5 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document |
| November 25, 2022 Filed Nov 28, 2022 22:02 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 11,135 | $35.18 | $391,684.76 |
DisclosureSEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · nonDerivative · entry 4 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 789,434 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.36, inclusive. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 25, 2022 Filed Nov 28, 2022 22:02 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 17,794 | $9.56 | $170,110.64 |
DisclosureSEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · nonDerivative · entry 3 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 22:02 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,616 | $0.00 Strike: $9.56 | $0.00 |
DisclosureSEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · derivative · entry 7 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,794 Underlying: Common Stock · 3,616 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F5 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 22:02 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 2,259 | $35.05 | $79,188.79 |
DisclosureSEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 782,775 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.23, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 23, 2022 Filed Nov 28, 2022 22:02 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 3,616 | $9.56 | $34,568.96 |
DisclosureSEC source: 0001104659-22-122479 · tm2231406-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 959 | $0.00 Strike: $9.56 | $0.00 |
DisclosureSEC source: 0001104659-22-121796 · tm2231250-1_4seq1.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,410 Underlying: Common Stock · 959 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F4 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 600 | $35.00 | $21,001.08 |
DisclosureSEC source: 0001104659-22-121796 · tm2231250-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,418 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.02, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 959 | $9.56 | $9,168.04 |
DisclosureSEC source: 0001104659-22-121796 · tm2231250-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 782,018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 848 | $0.00 Strike: $9.56 | $0.00 |
DisclosureSEC source: 0001104659-22-121285 · tm2231147-1_4seq1.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,369 Underlying: Common Stock · 848 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F4 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 531 | $35.01 | $18,592.22 |
DisclosureSEC source: 0001104659-22-121285 · tm2231147-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,059 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.04, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 21, 2022 Filed Nov 22, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 848 | $9.56 | $8,106.88 |
DisclosureSEC source: 0001104659-22-121285 · tm2231147-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,783 | $0.00 Strike: $9.56 | $0.00 |
DisclosureSEC source: 0001104659-22-119930 · tm2230682-1_4seq1.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,217 Underlying: Common Stock · 1,783 shares Expires 2024-01-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F4 · derivative.exercise_date: The options vested in four equal annual installments beginning on January 23, 2015. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
SaleCommon Stock | 1,115 | $35.00 | $39,028.01 |
DisclosureSEC source: 0001104659-22-119930 · tm2230682-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 780,742 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.03, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 22:00 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 1,783 | $9.56 | $17,045.48 |
DisclosureSEC source: 0001104659-22-119930 · tm2230682-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 15, 2022. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 22:01 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,800 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-22-119181 · tm2230256-2_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,800 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on January 21, 2015. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 22:01 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 6,800 | $34.95 | $237,655.24 |
DisclosureSEC source: 0001104659-22-119181 · tm2230256-2_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.90 to $35.110, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 11, 2022 Filed Nov 15, 2022 22:01 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 6,800 | $9.24 | $62,832.00 |
DisclosureSEC source: 0001104659-22-119181 · tm2230256-2_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-22-118708 · tm2230256-1_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 700 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on January 21, 2015. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
SaleCommon Stock | 700 | $34.97 | $24,479.91 |
DisclosureSEC source: 0001104659-22-118708 · tm2230256-1_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,644 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.90 to $35.145, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| November 09, 2022 Filed Nov 14, 2022 22:00 UTC |
Bhatt Padmanabh P.Sr. VP of IP, CSO
|
Exercise / conversionCommon Stock | 700 | $9.24 | $6,468.00 |
DisclosureSEC source: 0001104659-22-118708 · tm2230256-1_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 8, 2022. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 21:15 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionStock Appreciation Right · Derivative | 5,895 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-22-100486 · tm2225575-1_4seq1.xml · derivative · entry 5 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,895 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The SAR vested in four equal annual installments beginning on February 5, 2014. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 21:15 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 1,380 | $33.75 | $46,575.00 |
DisclosureSEC source: 0001104659-22-100486 · tm2225575-1_4seq1.xml · nonDerivative · entry 2 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 780,074 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person. F2 · price: The price reported in Column 4 is the closing price of the common stock on August 29, 2022, the date of the SAR's exercise, as reported by NASDAQ Stock Market, LLC. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 21:15 UTC |
Khattar Jack A.Director · President, CEO
|
Exercise / conversionCommon Stock | 5,895 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-100486 · tm2225575-1_4seq1.xml · nonDerivative · entry 1 Khattar Jack A. · CIK 0001539937 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,454 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2022 Filed Aug 23, 2022 21:16 UTC |
Martin Tami TillotsonSr. V.P., Regulatory Affairs
|
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-22-093748 · tm2223647-3_4seq1.xml · derivative · entry 3 Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022. F2 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 5, 2014. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.